Literature DB >> 27081284

Mucocutaneous Telangiectasia as a Diagnostic Clue of Hereditary Hemorrhagic Telangiectasia: An Activin Receptor-Like Kinase-1 Mutation in a Korean Patient.

Jimyung Seo1, Howard Chu1, Jin Sung Lee2, Do Young Kim1.   

Abstract

Entities:  

Year:  2016        PMID： 27081284      PMCID： PMC4828400          DOI： 10.5021/ad.2016.28.2.264

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN： 1013-9087            Impact factor:   1.444


× No keyword cloud information.
  5 in total

1.  Cutaneous lesions in hereditary haemorrhagic telangiectasia: successful treatment with the tunable dye laser.

Authors:  R U Dave; P J Mahaffey; B E Monk
Journal:  J Cutan Laser Ther       Date:  2000-12

Review 2.  Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment.

Authors:  Claire L Shovlin
Journal:  Blood Rev       Date:  2010-09-25       Impact factor: 8.250

3.  A case of hereditary hemorrhagic telangiectasia.

Authors:  Ha Eun Lee; Chan Sagong; Kwang Yeoll Yeo; Joo Yeon Ko; Joung Soo Kim; Hee Joon Yu
Journal:  Ann Dermatol       Date:  2009-05-31       Impact factor: 1.444

4.  Treatment of the skin manifestations of hereditary hemorrhagic telangiectasia with pulsed dye laser.

Authors:  Shlomit Halachmi; Hadar Israeli; Dan Ben-Amitai; Moshe Lapidoth
Journal:  Lasers Med Sci       Date:  2013-05-17       Impact factor: 3.161

5.  Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic telangiectasia in France.

Authors:  Gaëtan Lesca; Henri Plauchu; Florence Coulet; Sylvain Lefebvre; Ghislaine Plessis; Sylvie Odent; Sophie Rivière; Bruno Leheup; Cyril Goizet; Marie-France Carette; Jean-François Cordier; Stéphane Pinson; Florent Soubrier; Alain Calender; Sophie Giraud
Journal:  Hum Mutat       Date:  2004-04       Impact factor: 4.878
  5 in total
  2 in total

1.  First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors.

Authors:  Jessica J Tao; Nicholas A Cangemi; Vicky Makker; Karen A Cadoo; Joyce F Liu; Drew W Rasco; Willis H Navarro; Christopher M Haqq; David M Hyman
Journal:  Clin Cancer Res       Date:  2019-05-08       Impact factor: 12.531

2.  Myopenia and precision (P4) medicine.

Authors:  John E Morley; Stefan D Anker
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-09-24       Impact factor: 12.910
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.